Base metrics
- Operating margin
- -12.9%
- Interest coverage
- -1.8x
- Return on equity (ROE)
- -913.1%
Evolus financial statements
에볼러스NASDAQ:EOLS · Nasdaq · Healthcare$7.74+4.88%
2026-10-07 closeEvolus's published financial data is dated 2026-10-04. 2024 revenue was $266M. 2024 operating profit was −$34M.
Reported results
Financial safety
Reference indicatorAs of 2024Distress zoneFinancial-metric reference signal
Altman Z'' zoneZ'' -7.02
Distress
Grey
Safe
- Altman Z''
- -7.02
- Beneish M-Score
- -2.65
- Sloan accrual
- -13.94%
No statistical flag
부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.
Factual information, not investment advice.
Earnings quality · Piotroski F-Score
6/9Moderate
Piotroski measures year-over-year financial improvement, not absolute quality.
Financial improvement score6/9
Profitability
- Positive ROANot passed
- Positive OCFNot passed
- Improving ΔROAPass
- Accruals (OCF > net income)Pass
Leverage & liquidity
- Lower debtPass
- Higher current ratioPass
- No new sharesPass
Efficiency
- Higher gross marginNot passed
- Higher asset turnoverPass
Calculation note: F7(신주)은 equity/asset 유지로 근사
Already-stable companies may score lower when year-over-year improvement is limited.
Factual information, not investment advice.
Risk sensitivity — adverse assumptions
Metric changes under stated assumptions; not a forecast or investment advice.
Operating margin −5pp
Operating lossInterest coverageBase -1.8x adverse case -2.5x
Return on equity (ROE)Base -913.1% adverse case -1,203.5%
Revenue −15%
Interest coverage riskInterest coverageBase -1.8x adverse case -1.6x
Return on equity (ROE)Base -913.1% adverse case -869%
Interest rate +2pp
Interest coverage riskInterest coverageBase -1.8x adverse case -1.5x
Return on equity (ROE)Base -913.1% adverse case -1,044.7%
Interest coverage limit
Already below the limit by 20ppInterest coverage limit at an operating margin of 7%
Interest expense coverage threshold
Quantus Signal · live data · not investment advice · Privacy Policy